Sunshine Lake Pharma (06887.HK) has successfully completed its merger with Dongguangyang Changjiang Pharmaceutical and commenced trading on the Main Board of the Hong Kong Stock Exchange as of August 7, 2025.

Post-merger, the company will integrate its industry-leading R&D expertise and global strategic framework to establish a fully closed-loop ecosystem encompassing research, production, and commercialization. Propelled by its dual strategic pillars of “Innovation + Global Expansion,” Sunshine Lake Pharma is positioned to accelerate the development of high-potential breakthrough therapies, enhance global commercialization efforts, and advance cross-border partnerships. This consolidation solidifies its role as a China-rooted, globally impactful leader in innovative pharmaceuticals.

“Medicine is a sacred calling. We are committed to delivering life-changing therapies for all and building Dongguangyang into a legacy enterprise spanning generations.” This guiding principle underscores the company’s mission. With this listing marking a pivotal milestone, Dongguangyang Pharma reaffirms its dedication to advancing global health and pioneering a new era of excellence in the biopharmaceutical industry.